Anavex Life Sciences
AVXL | NASDAQ
$0.82
-$0.11 (-12.16%)
At close: Nov 16, 2026, 4:00 PM ET
$0.85
+$0.03 (+3.66%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Anavex Life Sciences Company Profile
Company profile explainedCompany Profile
Operating as a clinical-stage biopharmaceutical entity, Anavex Life Sciences Corp. specializes in developing therapeutic drug candidates for various central nervous system (CNS) conditions. Its leading compound, ANAVEX 2-73, is currently in advanced development, undergoing Phase III clinical evaluation for both Alzheimer's disease and pediatric Rett syndrome. This same drug is also in Phase II trials for Parkinson's disease and is being explored in preclinical studies for a wider range of disorders, including epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Another significant drug candidate, ANAVEX 3-71, has progressed to Phase I clinical trials for frontotemporal dementia and other forms of dementia, with additional preclinical investigation underway for neurodegenerative illnesses like Alzheimer's and Parkinson's. The company's earlier-stage portfolio includes ANAVEX 1-41, a sigma-1 receptor agonist targeting depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand with potential applications in neuropathic and visceral pain; and ANAVEX 1037, aimed at treating prostate and pancreatic cancers. Anavex Life Sciences Corp. was founded in 2004 and maintains its headquarters in New York, New York.
Key Executives
| Name | Position |
|---|---|
| Terrie Kellmeyer | Interim Chief Executive Officer |
| Sandra Boenisch | Principal Financial Officer & Treasurer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 20, 2026 | 8-K | Current Report |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 3 | Filing |
| Oct 05, 2026 | 3 | Filing |
| Sep 28, 2026 | 4 | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 21, 2026 | DFAN14A | Filing |
| Sep 18, 2026 | DFAN14A | Filing |
| Sep 17, 2026 | DFAN14A | Filing |
| Sep 15, 2026 | DEFA14A | Filing |
Anavex Life Sciences
| Country | United States |
| IPO Date | Aug 2, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Terrie Kellmeyer |
Contact Details
630 5th Avenue New York City,
New York 10111 United States
Stock Details
| Ticker Symbol | AVXL |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001314052 |
| CUSIP Number | 032797300 |
| ISIN Number | US0327973006 |
| SIC Code | 2836 |
Add to Watchlist
Select watchlists to add or remove AVXL